Literature DB >> 8327847

The transferrin receptor: its diagnostic value and its potential as therapeutic target.

K Thorstensen1, I Romslo.   

Abstract

Transferrin receptors are present on almost all mammalian cells. The receptor participates in the cellular acquisition of iron from transferrin by receptor-mediated endocytosis. Receptor abundancy is generally regulated by two factors: i) cellular iron status and ii) cell growth. These two factors form the basis for the utilization of transferrin receptor determination as a diagnostic tool. In the assessment of body iron status and erythropoietic activity the measurement of circulating transferrin receptor has proved to be of value as a measure of mild tissue iron deficiency, to distinguish iron deficiency anemia from the anemias of chronic disease, and as a sensitive index of iron deficiency during pregnancy. Histochemical analysis of the presence and abundancy of the transferrin receptor will continue to serve as an additional tool in special cases to distinguish between malignant and normal cell growth, and to provide additional information about the biological behaviour of tumor cells. Finally, the transferrin receptor holds a potential as a target for direct and indirect drug delivery in the therapy of malignant cell growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327847     DOI: 10.3109/00365519309090703

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  11 in total

1.  Self-assembled Targeting of Cancer Cells by Iron(III)-doped, Silica Nanoparticles.

Authors:  K K Pohaku Mitchell; S Sandoval; M J Cortes-Mateos; J G Alfaro; A C Kummel; W C Trogler
Journal:  J Mater Chem B       Date:  2014-12-07       Impact factor: 6.331

Review 2.  [Molecular and parametric imaging with iron oxides].

Authors:  L Matuszewski; B Tombach; W Heindel; C Bremer
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

3.  Effects of cellular pharmacology on drug distribution in tissues.

Authors:  R K Rippley; C L Stokes
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

Review 4.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

5.  Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo.

Authors:  Kathleen F Pirollo; Antonina Rait; Qi Zhou; Xin-qiao Zhang; Jain Zhou; Chang-Soo Kim; William F Benedict; Esther H Chang
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

6.  Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery.

Authors:  Bong-Seop Lee; Manabu Fujita; Natalya M Khazenzon; Kolja A Wawrowsky; Sebastian Wachsmann-Hogiu; Daniel L Farkas; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

7.  Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases.

Authors:  Matthew Freedman; Esther H Chang; Qi Zhou; Kathleen F Pirollo
Journal:  Acad Radiol       Date:  2009-05       Impact factor: 3.173

8.  Prevalence of Anaemia and Evaluation of Transferrin Receptor (sTfR) in the Diagnosis of Iron Deficiency in the Hospitalized Elderly Patients: Anaemia Clinical Studies in Chile.

Authors:  Mauricio López-Sierra; Susana Calderón; Jorge Gómez; Lilian Pilleux
Journal:  Anemia       Date:  2012-05-03

9.  Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro.

Authors:  Upendhar Gandapu; R K Chaitanya; Golla Kishore; Raju C Reddy; Anand K Kondapi
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

10.  An efficient targeted drug delivery through apotransferrin loaded nanoparticles.

Authors:  Athuluri Divakar Sai Krishna; Raj Kumar Mandraju; Golla Kishore; Anand Kumar Kondapi
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.